6 citations
,
February 2013 in “Medical Oncology” Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.
December 2004 in “SUNScholar (Stellenbosch University)” Certain genetic markers can indicate a person's risk of developing prostate cancer.
18 citations
,
April 2011 in “International Journal of Molecular Medicine” Dihydrotestosterone causes p27 protein breakdown in ovarian and breast cancer cells by binding with SKP2.
53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
50 citations
,
December 2006 in “Bone” Exemestane may protect bones by stimulating osteoblast growth through androgen-related pathways.
12 citations
,
February 2023 in “Applied and Environmental Microbiology” Mutants of CYP154C2 enzyme significantly improved steroid conversion efficiency.
21 citations
,
November 2017 in “Archives of Dermatological Research” Higher enzyme levels found in women with hair loss, suggesting hormone imbalance.
3 citations
,
April 2024 in “Molecular Human Reproduction” Paxillin may help manage androgen-related disorders like PCOS by stabilizing androgen receptor proteins.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
4 citations
,
August 2010 in “Acta Biologica Hungarica” New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
30 citations
,
June 2010 in “Endocrine Related Cancer” SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
1 citations
,
November 2024 in “Archives of Dermatological Research”
7 citations
,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
October 2025 in “Journal of the Endocrine Society” Anastrozole can cause increased testosterone, leading to symptoms like hair growth and thinning.
8 citations
,
June 2023 in “European Journal of Endocrinology” The inhibitor affects androgen metabolism but not ovarian function.
December 2023 in “International Journal of Molecular Sciences” Men with early balding showed higher levels of certain genes linked to hair loss and possibly prostate cancer.
3 citations
,
January 2008 in “Endocrine journal” A new mutation linked to partial Androgen Insensitivity Syndrome and prostate cancer was found in a patient unhappy with their female gender assignment.
December 2023 in “International journal of molecular sciences” Chromosomal differences affect how muscle cells respond to testosterone.
May 2026 in “ACS Catalysis” Efficient enzyme function relies on specific residue interactions and structural coordination.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
55 citations
,
May 2019 in “Journal of Endocrinology” Androgens are important for female fertility and could help in IVF treatment, but also play a role in causing PCOS.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
21 citations
,
January 2015 in “The Journal of Steroid Biochemistry and Molecular Biology” Progesterone byproduct 5αP stimulates mammary tumor growth, but finasteride can suppress it.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
34 citations
,
November 2013 in “Breast Cancer Research and Treatment” Aromatase inhibitor therapy for breast cancer increases the risk of hair loss and thinning.
January 2004 in “Pharmaceutical biotechnology” Finasteride effectively inhibits the enzyme steroid 5 alpha-reductase II.
63 citations
,
November 1999 in “British journal of dermatology/British journal of dermatology, Supplement” Hair sensitivity to androgens is partly controlled by specific enzyme expressions in different hair areas.
August 2024 in “Latin American Journal of Development” 5α-reductase enzymes are crucial in certain disorders, and while treatment advances exist, more research on SRD5A3 is needed.
14 citations
,
April 2024 in “The Journal of Steroid Biochemistry and Molecular Biology” 5α-reductases increase epitestosterone's effect on androgen receptors.